Takeda Pharmaceutical Co (4502.T) Stock Price
Takeda Pharmaceutical Co Price
Revenue has compounded at 6.7% per year over the past 19 years to 4.51 T JPY. Earnings per share have declined at 2.9% per year over the last 19 years. Takeda Pharmaceutical Co's net margin stands at 4.3%, down from 6.4% several years earlier. Takeda Pharmaceutical Co currently offers a dividend yield of about 4.27%. The payout ratio is around 201% of earnings. The dividend has grown at 3.6% per year over the past 19 years. Analysts set a median price target of 5,610.00 JPY, implying 19.7% below the current price. Of 19 analysts, 11 rate the stock a buy — an overall Buy consensus.
Takeda Pharmaceutical Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Takeda Pharmaceutical Co business model & stock analysis
Frequently asked questions about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co Ltd. operates under a research-based pharmaceutical business model. As a leading global biopharmaceutical company, Takeda focuses on discovering, developing, and distributing innovative medicines and healthcare solutions. The company is committed to improving the health and well-being of people worldwide through its strong portfolio of prescription drugs and therapies. Takeda's business model emphasizes leveraging its expertise in areas such as oncology, gastroenterology, neuroscience, and rare diseases to deliver life-changing treatments and therapies. With a dedication to innovation and collaboration, Takeda remains at the forefront of advancing healthcare and improving patient outcomes.
Takeda Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Takeda Pharmaceutical Co Ltd in the market include multinational pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies are prominent players in the global pharmaceutical industry, with a diverse range of healthcare products and a significant market presence. Takeda Pharmaceutical Co Ltd faces competition from these established competitors in various therapeutic areas, including oncology, gastroenterology, and rare diseases. The company strives to maintain its competitive edge by leveraging its research and development capabilities, innovative product portfolio, and strategic collaborations, allowing it to compete effectively in the dynamic pharmaceutical market.
Takeda Pharmaceutical Co Ltd is a renowned pharmaceutical company with a rich history and strong global presence. Founded in 1781 in Osaka, Japan, Takeda has grown to become one of the largest pharmaceutical companies in the world. Over the years, Takeda has focused on research and development, manufacturing, and marketing of a wide range of pharmaceutical products. With a commitment to improving the health of people worldwide, they have expanded their operations to over 80 countries. Takeda's success can be attributed to its dedication to innovation, high-quality products, and a focus on patient-centered healthcare solutions. Today, Takeda remains at the forefront of the industry, striving to address unmet medical needs and improve patients' lives globally.
Takeda Pharmaceutical Co Ltd has achieved numerous significant milestones throughout its history. One key accomplishment was its establishment in 1781, making it one of the oldest pharmaceutical companies in Japan. Takeda has continued to innovate and excel in the healthcare industry, expanding its global presence and becoming the largest pharmaceutical company in Asia. It has made groundbreaking advancements in various therapeutic areas, such as gastroenterology, oncology, and neuroscience. Takeda's acquisition of Shire in 2019 further solidified its position as a leading global biopharmaceutical company. These achievements highlight Takeda Pharmaceutical Co Ltd's commitment to improving lives through its innovative medicines and therapies.
Takeda Pharmaceutical Co Ltd is primarily present in various countries and regions worldwide. As a leading global pharmaceutical company, Takeda operates in multiple key markets, including Japan, the United States, Europe, and emerging markets in Asia, Latin America, and Africa. With a strong international presence, Takeda continues to expand its reach to bring innovative medicines and healthcare solutions to patients across the globe.
Takeda Pharmaceutical Co Ltd represents a focus on values and corporate philosophy that prioritize patient-centricity, integrity, and dedication to improving people's lives. Takeda is committed to delivering innovative and high-quality medicines, aiming to contribute to the health of patients worldwide. With a legacy spanning over 239 years, Takeda upholds a core mission to strive towards better health and a sustainable future. Their dedication to ethical practices, collaborative partnerships, and continuous innovation reinforces Takeda Pharmaceutical Co Ltd's position as a leading global pharmaceutical company.
Analysts currently set an average price target of 5,456.69 JPY for the Takeda Pharmaceutical Co stock (median: 5,610.00 JPY), implying -21.8 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Takeda Pharmaceutical Co stock: 11 recommend buying, 8 holding and 0 selling.
Converted at the current exchange rate, the Takeda Pharmaceutical Co share trades at 39.81 EUR (6,982.00 JPY).
The Takeda Pharmaceutical Co share (4502.T) is listed on 8 stock exchanges, including: London (0RN3.L), Tokio (JPX) (4502.T), Frankfurt (TKD.F), München (TKD.MU), Düsseldorf (TKD.DU), Hamburg (TKD.HM), Wien (TKD.VI).
Takeda Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1781. It is headquartered in Osaka and currently employs over 49,000 people worldwide. The company operates in over 70 countries and offers a wide range of innovative medicines. Takeda focuses on the fields of internal medicine, oncology, gastroenterology, and neurology.
The revenue of Takeda Pharmaceutical Co is 4.51 T JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Takeda Pharmaceutical Co is 191.76 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Takeda Pharmaceutical Co is currently 56.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Takeda Pharmaceutical Co stock.
The price-to-sales ratio (P/S) of Takeda Pharmaceutical Co is currently 2.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Takeda Pharmaceutical Co stock.
The Eulerpool Quality Score for Takeda Pharmaceutical Co is 3/10.
The ISIN of Takeda Pharmaceutical Co is JP3463000004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Takeda Pharmaceutical Co is 853849. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Takeda Pharmaceutical Co is 4502.T. The ticker symbol is used to trade Takeda Pharmaceutical Co shares on the stock exchange.
Takeda Pharmaceutical Co stock
Takeda Pharmaceutical Co Peer Group
Takeda Pharmaceutical Co Ticker
Takeda Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Takeda Pharmaceutical Co
Our stock analysis for Takeda Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takeda Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.